About KD Ventures
KDventures is a listed Nordic life science investment company that invests in and develops innovative pharmaceutical, biotech and medical technology companies. Through specialist expertise, active ownership and a focused portfolio, we work to address major medical needs and create long-term value.
2003
KDventures was founded
20+
years of experience in life science
1300+
innovations evaluated
60+
companies developed and financed
We invest in the life science of the future
We seek Nordic life science companies with differentiated innovations, clear medical needs and the potential to achieve clinical and commercial success. We primarily focus on projects that have progressed beyond the very earliest research and where clear milestones can drive development and create value.
Our investments span pharmaceuticals, biotechnology and medical technology. What the companies have in common is the potential to improve how serious diseases are prevented, diagnosed or treated.
An active owner driving the next step
Strategic advice
We help companies prioritise correctly and choose a clear path towards clinical and commercial success.
Operational follow-up
We monitor studies, milestones, liquidity, financing needs and risks throughout the development process.
Financing and capital strategy
We support capital raising and direct resources towards the most important value drivers.
Board work and corporate governance
Through active board work, we contribute to clear decisions, the right organisation and strong governance.
Network and specialist expertise
We combine life science expertise with experience in investments, financing and transactions.
Partnerships and transactions
We position companies for partnerships, licensing agreements, sales and stock market listings.
A mature portfolio with clear value drivers
KDventures has over 20 years of experience investing in life science and has for a long time invested significant capital and resources in developing its portfolio companies. Several of the companies have now reached mature clinical and commercial positions, with projects in or on the way to later development phases.
In the coming years, several important study results and other value-driving milestones are expected. Positive outcomes can strengthen the opportunities for larger licensing agreements, industrial partnerships, financings or sales, thereby creating significant value for KDventures shareholders.
We invest in the life science of the future
Life science includes pharmaceuticals, biotechnology and medical technology aimed at preventing, diagnosing and treating diseases. The sector is driven by scientific advances and a great need for new and better treatments.
A significant part of innovation takes place in smaller, specialised companies that develop new treatments with funding from investors. When projects have progressed far enough, larger pharmaceutical companies can provide the financing, development capacity and global organisation required to take them further through licensing agreements, partnerships or acquisitions.
Positive clinical results and other important advances can therefore create significant value long before a product reaches the market. At the same time, development is lengthy, capital-intensive and associated with risk, making specialist expertise, a long-term approach and risk diversification particularly important.
Over 20 years of life science investing
From medical progress to realised value
Value is built when portfolio companies reach clinical, regulatory and commercial milestones. It can then be realised through licensing agreements, industrial partnerships, the sale of all or parts of a company, or through a stock market listing.
The most suitable route is assessed based on each company's development, financing needs and commercial opportunities.
A focused portfolio with clear value drivers
KDventures' portfolio mainly consists of companies with projects in clinical or commercial development. Several of the companies are approaching important study results, regulatory advances, financings and partnerships that may be of great importance for their continued development.
By being exposed to several companies and projects, multiple possible routes to value are created. We prioritise the holdings where upcoming milestones can have the greatest value impact and where KDventures has good opportunities to influence development.
Exposure to Nordic life science
By investing in KDventures, shareholders gain exposure to several Nordic life science companies and medical innovations at different stages of development. Our task is to combine specialist expertise, active ownership and capital discipline to create the conditions for long-term shareholder value.